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Abstract
Static cold storage is currently the most used method of organ
preservation worldwide. However, cutting edge technology and
dramatic changes in the donor pattern have lately renewed the interest
toward hypothermic machine perfusion. Marginal and cardiac death
donors show higher rates of primary non function and delayed graft
function compared to standard criteria donors. In this setting, machine
perfusion may offer several theoretical advantages such as improved
organ preservation, continuous graft evaluation, and ex-vivo
conditioning of the graft before implantation. These topics have been
recently reassessed by several studies. In particular, perfusion
characteristics (renal resistance) and perfusate biomarker
concentrations (lactate dehydrogenase, aspartate aminotransferase,
heart-type fatty acid binding protein, and IL-18) during machine
preservation, proved to be reliable tools to rule out graft viability and
predict outcomes after transplantation. Treatment strategies acting on
tissue repair, cell metabolism, and allorecognition pathway are also
under investigation with promising results. Machine perfusion has
finally shown its real potential however, stronger evidences and
updated cost-effectiveness analysis are needed to fully support its role
for the next future.
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Abbreviations
DBD: Donation after Brain Death; ECD: Expanded Criteria Donor;
DCD: Donation after Cardiac Death; PNF: Primary Non Function;
DGF: Delayed Graft Function; HMP: Hypothermic Machine
Perfusion; GS: Graft Survival; RR: Renal Resistance; LDH: Lactate
Dehydrogenase; AST: Aspartate amino-Transferase; GST: Glutathione-
S-Transferase; HFABP: Heart-type Fatty Acid Binding Protein; NAG:
N-Acetyl-β-D-Glucosaminidase; MDA: Malondialdehyde.
Introduction
Kidney transplantation is the treatment of choice of end stage renal
disease [1]. Impressive advances in organ procurement, surgical
technique, post-operative care, and immunosuppression have
significantly reduced transplant-related morbidity and mortality
transforming an extraordinary event in a safe and routinely performed
procedure.
In an attempt to expand the donor pool and match the increasing
amount of patients in the waiting lists, the transplant community has
more recently moved from the traditional boundaries set by the
standard donation after brain death (DBD) toward the new frontiers of
expanded criteria donors (ECD) [2,3] and donation after cardiac death
(DCD) [4,5]. However, compared to kidneys retrieved from standard
donors, ECD and DCD organs show higher rates of primary failure
(PNF) and delayed graft function (DGF) [3-6]. Inferior renal function
and higher discard rates have been also highlighted by several reports.
In this setting, optimal preservation, reliable assessment, and possibly
ex-vivo conditioning of the graft before implantation become
extremely important.
Cold storage (literally in ice) has been serving our cause for almost
sixty years. Ideal organ quality, favorable transport requirements, and
economic reasons have been the main factors behind the supremacy of
this preservation modality. Nevertheless, the dramatic changes
observed in the transplantation scenario during the last two decades
combined with modern technologies, have once again raised interest
into an old but renewed ally: hypothermic machine perfusion (HMP).
First introduced into the clinical practice by F.O. Belzer in the late
sixties, the new generation of portable hypothermic perfusion
machines offers several advantages over traditional hypoxic flush
preservation and cold storage [7,8].
Organ Preservation
From the physiological point of view, controlled hypothermia
(4-10°C) allows homogeneous cooling of the kidney with reduced but
still preserved metabolism. Such a low degree of cellular activity does
actually help tissues continue the reparative process triggered by the
retrieval and does improve the ability of the organ to effectively cope
with the future damages of the ischemia-reperfusion injury. The
opportunity to deliver oxygen to the cells through normal air tension,
external oxygenation, or even oxygen carriers released into the
preservation fluid, represents another important feature of machine
perfusion. Oxygen supply is needed to keep mitochondrial function
ensuring adequate energy production and correct ionic balance during
storage. Moreover, continuous or pulsatile perfusion granted by the
machine, prevents the collapse of the capillary bed with a wider
distribution of the preservation solution and a more effective washout
of toxic metabolites, clots, and debris.
All those theoretical benefits have been recently investigated in
three randomized clinical trials in DBD, ECD, and DCD kidney
transplantation. In their original work dated 2009 [9] and in the
extension trial published in 2012 [10], Moers and colleagues observed
significantly lower rates of DGF and better graft survival in DBD and
ECD kidneys preserved with hypothermic machine perfusion
compared to cold storage (3-year GS: 91% vs. 86% and 86% vs. 76%,
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respectively). Beneficial effects of HMP were more evident in
transplants from marginal donors and for DBD transplants not
experiencing DGF. Lower rates of DGF were also reported for
machine-perfused DCD kidneys, but the study failed to demonstrate
any survival advantages in this subgroup of recipients. Conflicting
results were reported by two other trials addressing the same topics in
Maastricht Category III DCD donors. In the first trial [11], performed
under Eurotransplant, 155 kidneys pairs were randomized to
immediate machine perfusion or static cold storage. DGF was
observed in 53.7% of the organs allocated to HMP and in 69.5% of the
graft preserved in ice (p<0.05). Functional DGF (i.e. absence of a
decrease in serum creatinine level by a minimum of 10% per day
during three consecutive days in the first post-operative week) showed
a similar trend (19.5% vs. 51.2%, respectively). There were no
differences in PNF, acute rejection, and 1-year graft survival rates
between the two groups. Similar 1-year graft survival (93.3% vs. 97.8%)
and renal function were reported by the randomized clinical trial
performed in UK in 2010 [12]. Surprisingly, the study showed no
differences in DGF rates between HMP and cold storage (58% vs. 56%)
but the fact that some of the kidneys allocated to HMP were actually
put on ice before effective pumping may somehow explain this
unexpected finding.
Although more updated cost-effectiveness analysis are still needed
[13], current trends seem to support the use of HMP for DBD kidneys
[14], especially from marginal donors [15]. Indeed, kidneys preserved
on HMP show lower rates of DGF compared to cold storage and it is
well recognized that DBD and ECD transplants experiencing DGF do
have an increased risk of acute rejection, poor graft function, and graft
failure [16]. As a matter of fact, DCD kidneys have higher rates of PNF
and DGF compared to age-matched DBD organs. However, for some
reason still unknown, DGF does not significantly impact long term
DCD transplant outcomes [17]. It has been postulated that organ
damages caused by the events initiated by brain death can be very
different from the ones potentially triggered by cardio-circulatory
death [18, 19]. As a consequence, HMP may not be actually able to
address the specific needs of DCD kidneys during preservation.
Theoretically, uncontrolled DCD (mainly Maastricht Category I and
II) may exhibit a different behavior compared to controlled DCD
(Category III) but good quality studies in this field have yet to be
published.
Organ Assessment
HMP allows real time evaluation of the organ before implantation
through tissue sampling, continuous assessment of the quality of the
perfusion, and timely analysis of the perfusate. The possibility to test
the kidney during machine preservation is not something new as
studies addressing this issue were already available thirty years ago.
Nevertheless, modern technologies combined with current
understanding of cell biology can offer a complete different set of
information compared to the past.
Several studies have suggested that perfusion parameters during
machine preservation can predict transplant outcomes but until
recently almost only retrospective analysis have been performed. In his
prospective trial evaluating HMP parameters in DBD, ECD, and DCD
kidney transplants [20] Jochmans demonstrated that vascular renal
resistance (RR) is an independent risk factor for DGF and 1-year graft
failure. However, no reliable cut off value truly predictive of DGF could
be found and there was no correlation between RR and PNF. In other
two prospective studies [21,22]. Yushkov showed that RR > 0.3
mmHg/mL/min is associated with poor 1-year graft survival. Higher
rates of PNF were described by de Vries and his group [23] in
Maastricht Category III DCD kidneys with high RR early during
machine perfusion.
Those results seem to validate RR for organ assessment but need to
be cautiously interpreted as unable to provide a definitive parameter
that could be reliably used to evaluate graft viability and function
before implantation [24]. Avoiding unsuccessful transplants is
obviously a major concern but the risk we may discard good quality
kidneys remains too high if RR, is not combined with other prognostic
factors [25, 26]. Indeed, more powered studies are still required to
definitely address this issue.
Another strong point of HMP is the opportunity to further evaluate
organ viability and quality through non-invasive analysis of the
composition of the perfusate during preservation. Ideally, perfusate
biomarkers can give us dynamic information on previous organ
damage, active metabolism, ongoing reparative process, and expected
transplant outcomes. At the moment, perfusate testing is mainly based
on bio-chemical methods but more sophisticated assays such as
proton-nuclear magnetic resonance spectroscopy are under
investigation [27]. Many molecules have been studied so far but only
few showed significant association with important post-transplant end
points in multivariate analysis [28]. Lactate dehydrogenase (LDH) and
aspartate aminotransferase (AST), well known non-specific markers of
tissue damage, proved to be highly predictive of DGF in DBD and
DCD kidney transplants [29]. Associations between PNF and graft
function have been also reported but evidences remain overall weak.
Glutathione-S-transferase (GST), a more specific marker of renal
tubular injury, and Heart-type fatty acid binding protein (HFABP),
generally released under ischemic conditions, have also shown good
correlations with DGF [29]. Other biomarkers of potential interest as
implicated in the process of ischemia/reperfusion injury are N-acetyl-
β-D-glucosaminidase (NAG) [29], malondialdehyde (MDA) [30],
redox-active iron [31], and IL-18. IL-18 in particular, released by
mononuclear cells in response to oxidative stress, has been associated
with PNF in controlled and uncontrolled DCD kidney transplants
[28].
Despite promising results, perfusate biomarkers as well as perfusion
parameters cannot be considered an absolute indicator of graft
viability. Combining different biomarkers is the best strategy to
overcome their individual lack of sensitivity and specificity but the risk
of bursting money without having a definitive answer to our question
remain significant. Too many variables do play a role before, during,
and after preservation and probably the best way to assess a kidney is
to consider donor characteristics, macroscopic evaluation, histology,
HMP parameters, and perfusate biomarkers all together. A
comprehensive score taking into account all these information can
more likely find its place as a reliable albeit not definitive toll for
helping clinicians discard not viable organs, chose the right kidney for
the right recipient, and select the most appropriate immunosuppressive
treatment after transplantation [32-35].
Ex-vivo Conditioning
Administration of different oxygen concentrations has been the first
step toward more complex attempts to improve transplant outcomes
through direct conditioning of the graft during preservation [36,37].
Experimental models addressing how to deliver cytoprotective
mixtures, immune modulators or even immunosuppressive agents
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during HMP so as to prevent or reduce ischemia-reperfusion injury
and rejection are under development [38-40]. In the future, stem cells
treatment [41] and targeted gene therapy [42] toward donor organs
will probably make the difference between the old age and the new era
of transplantation but, at the moment, reports remain anecdotal.
Conclusion
HMP is the ideal methods of preservation for DBD and ECD
kidneys as it shows lower rates of PNF and DGF compared to cold
storage. Further studies are warranted to definitely address this issue in
DCD kidney recipients. Renal resistance during preservation is
significantly associated with important transplant outcomes such as
DGF and early graft survival but no reliable cut off values have been
yet identified. More specific studies addressing this issue in controlled
and uncontrolled DCD kidneys are therefore needed to reach firm
conclusions. Perfusate biomarker concentrations, especially LDH, AST,
HFABP and IL-18 showed good correlation with graft viability, PNF or
DGF but their lack of specificity and sensitivity strongly suggests to
match results with other donor and graft characteristics. Ex-vivo
conditioning of the graft before implantation through stem cells
transfer or targeted gene therapy is now technically possible but many
years will pass before it will find a proper place in clinical practice. As
soon as more updated cost-effectiveness analysis of HMP will be
available we will finally understand that sometimes what comes from
the past can more easily bring as to the future.
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